此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

静脉铁剂与口服铁剂治疗缺铁性贫血的比较 (IDA)

2026年11月4日 更新者:Arrowhead Regional Medical Center

Early Intravenous Versus Oral Iron for Ferritin-Defined Iron Deficiency in Pregnancy: A Prospective Comparative Study

This study aims to assess whether administering intravenous iron early in pregnancy, compared to standard oral iron treatment, can enhance hemoglobin levels before delivery and reduce the need for blood transfusions in patients with iron deficiency anemia. Patients diagnosed with iron deficiency anemia were randomly assigned to receive either oral or intravenous iron. Before treatment initiation, patients completed a symptom questionnaire baseline hemoglobin, and ferritin levels were measured. Follow-up visits occurred four weeks later and at 24 to 28 weeks gestation, involving reassessment of symptoms, laboratory testing, and monitoring of treatment adherence. Final hemoglobin levels were determined before delivery, and data on the need for blood transfusion at delivery were recorded.

研究概览

详细说明

Iron deficiency anemia is a prevalent health concern affecting approximately a quarter of the global population. In specific high-risk subgroups such as pregnancy, the occurrence of anemia is even higher. This condition is associated with adverse outcomes such as increased risks of blood transfusion, longer hospital stays, slower recovery, and depression, along with pregnancy risks such as preterm birth and low birth weight. Furthermore, infants born to iron-deficient mothers are at risk for delayed childhood growth and cognitive development. Preoperative optimization is crucial for improving clinical outcomes, as iron deficiency anemia accounts for over 80% of anemia cases in these patients.

Traditionally, oral (PO) iron supplementation has been the standard approach recommended by the American College of Obstetrics and Gynecology (ACOG) for preventing and addressing iron deficiency due to its simplicity and cost-effectiveness. However, it is marred by poor adherence to therapy and a high incidence of gastrointestinal side effects. While numerous publications have documented the safety and efficacy of intravenous (IV) iron, its utilization remains limited. Currently, IV iron is primarily reserved for patients who exhibit intolerance or an inadequate response to oral therapy. At our institution, we have taken proactive steps by administering IV iron infusions to many of our patients at an earlier gestational age, given the high rate of non-compliance with oral iron therapy. Our hypothesis proposes that individuals with iron deficiency anemia, defined as a serum ferritin level of less than 30 ng/mL (with 92% sensitivity and 98% specificity compared to hemoglobin (Hgb) levels), who receive IV iron infusions, will achieve higher Hgb levels upon admission and experience reduced rates of blood transfusions.

This study aims to assess the impact of IV iron infusions on pregnant patients with iron deficiency anemia. We hope that implementing this study will help improve overall population health. We hypothesize that individuals with iron deficiency anemia who receive IV iron infusions will attain higher Hgb levels at the time of admission and experience reduced rates of blood transfusions at the time of delivery.

After obtaining the patient's consent, they will be allocated into either of the two treatment options. All odd numbers will be in the oral iron group and even numbers enrolled into the IV iron group. We intend to administer Ferrous sulfate 325 mg orally every other day on an empty stomach with lemon/orange water, as numerous randomized control trials have demonstrated that increasing the iron dose does not lead to improved efficacy. Venofer 200 mg will be given every other day until the patient reaches their calculated iron deficit. The dose of IV iron will be calculated according to the Ganzoni formula: total iron dose (mg) = body weight (kg) x (target Hgb - baseline Hgb (g/dL)) × 0.24 + 500 mg. Our target Hgb will be 11.0 g/dL.

Patients will be given a symptom questionnaire at the time of enrollment to fill out. We will analyze the patient's ferritin, iron, total iron binding capacity (TIBC), Hgb level, mean corpuscular volume (MCV), and Hgb electrophoresis, which are routinely obtained on the first visit with prenatal labs. Four weeks after initiating treatment, patients will fill out a symptom and side effect questionnaire, and if on PO iron, their compliance will be assessed. Complete blood count (CBC) and iron studies will be repeated at that time. Other patient information such as admission CBC, post-delivery CBC, height, weight, body mass index (BMI), age, parity, gestational age at delivery, quantitative blood loss, route of delivery, need for blood transfusion, number of IV iron infusions, fetal birth weight, and antepartum/intrapartum/postpartum complications such as diabetes, preeclampsia/eclampsia, chorioamnionitis, and hemorrhage, etc., neonatal intensive care unit (NICU) admission as well as Edinburgh depression screening results, will be obtained from medical records. This information will be used for secondary outcomes analysis and to ensure there are no confounding factors. Statistical comparisons between groups will be performed using the two-way T-test followed by Tukey's test, or post hoc Student-Newman-Keuls tests. A P < .05 will be considered a statistically significant difference among groups.

研究类型

介入性

注册 (实际的)

518

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • California
      • Colton、California、美国、92324
        • Arrowhead Regional Medical Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

女性

描述

Inclusion Criteria:

  • Age > 18 years of age
  • Ferritin level < 30 ng/mL
  • Single gestation
  • 14 0/7 to 34 6/7 weeks of gestation
  • Plan to deliver at Arrowhead Regional Medical Center (ARMC)

Exclusion Criteria:

  • Maternal age < 18 years of age
  • Hgb < 7
  • Incarcerated patients
  • Multifetal gestation
  • Acute liver/kidney disease
  • Active infections
  • Known hematological malignancy
  • Other causes of anemia such as alpha/beta thalassemia, sickle cell disease, Folate/B12 deficiency, and anemia of chronic diseases
  • Known hypersensitivity to IV iron
  • Severe symptoms of anemia requiring blood transfusion

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:交叉作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
有源比较器:Intravenous iron

Venofer 200 mg will be given every other day until the patient reaches their calculated in deficit dose. The does of IV iron will be calculated according to the Ganzoni formula: total iron dose (mg) = body weight (kg) x (target Hgb - baseline Hgb (g/dL)) × 0.24 + 500 mg.14 Our target Hgb will be 11.0 g/dL. The determination of the treatment duration and dosage will be based on the calculation of the iron deficit.

200 mg IV every 2 days until the targeted dose

其他名称:
  • 蔗糖铁
安慰剂比较:Oral iron

Ferrous sulfate 325 mg orally every other day on an empty stomach with lemon/orange water until delivery.

Take 1 tablet every other day with lemon/orange juice

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Hemoglobin difference
大体时间:Hemoglobin level obtained prior to treatment and then 4 weeks later

Change in hemoglobin level after intervention, larger difference mean more improvement in Hgb

Hemoglobin level obtained prior to treatment and then 4 weeks later
Ferritin difference
大体时间:Ferritin level obtained prior to treatment and then 4 weeks later

Change in ferritin level after intervention, larger difference mean more improvement in ferritin level

Ferritin level obtained prior to treatment and then 4 weeks later

次要结果测量

结果测量
措施说明
大体时间
Preterm delivery
大体时间:At the time of delivery

Comparing hemoglobin levels to gestational age at delivery

At the time of delivery
Depression
大体时间:Duration of the pregnancy (up to 40 weeks) and up to 2 months postpartum

Edinburgh postnatal depression scale at first prenatal visit and postpartum. 10 questions with total score between 0-30. Higher score indicated increase risk for depression.

Duration of the pregnancy (up to 40 weeks) and up to 2 months postpartum
Birthweight
大体时间:At time of delivery

Comparing birthweight to hemoglobin levels at time of admission

At time of delivery
Pre-delivery Hemoglobin
大体时间:Obtained at time of delivery

Comparing pre-delivery hemoglobin levels

Obtained at time of delivery
Symptoms
大体时间:4 weeks

Comparing number of anemia symptoms before and after treatment. There are 11 anemia symptoms on the questionnaire. Using a Likert scale from 0 (no symptoms) to 5 (severe symptoms) patient mark each one. The score is totaled up and can range from 0-55.

4 weeks
Rates of blood transfusion
大体时间:At time of delivery until 6 weeks postpartum

Comparing rates of blood transfusion at time of delivery between the 2 groups. The number of units transfused will be collected and compared among the groups

At time of delivery until 6 weeks postpartum
Persistent anemia
大体时间:4 weeks

Comparing the number of patients with Hgb < 10.5 after intervention

4 weeks
Treatment adherence
大体时间:4 weeks

Treatment adherence was assessed differently according to the assigned treatment group. In the oral iron group, adherence was evaluated using patient-reported responses to a follow-up survey regarding compliance with the prescribed alternate-day ferrous sulfate regimen. In the IV iron group, adherence was determined by reviewing infusion records to assess whether participants received the prescribed number of iron sucrose infusions based on their calculated iron deficit.

4 weeks
Adverse effects
大体时间:4 weeks

Medication-related adverse effects were assessed using a patient-reported survey. Participants were asked about symptoms or side effects experienced during treatment.

4 weeks
Blood loss
大体时间:At the time of delivery until 5 days postpartum

Estimated maternal blood loss (mL) at the time of delivery, as documented in the medical record.

At the time of delivery until 5 days postpartum
. Mode of delivery
大体时间:At the time of delivery

Mode of delivery, categorized as vaginal delivery or cesarean delivery, as documented in the medical record.

At the time of delivery
Apgar scores
大体时间:At time of delivery, 1 and 5 minutes

Neonatal Apgar scores at 1 and 5 minutes after birth, as documented in the medical record. Range 0 to 10

At time of delivery, 1 and 5 minutes
NICU admission
大体时间:At the time of delivery until 5 days postpartum

Admission to the neonatal intensive care unit (NICU) following delivery, recorded as yes or no.

At the time of delivery until 5 days postpartum
Neonatal hemoglobin
大体时间:At the time of delivery until 5 days postpartum

Neonatal hemoglobin concentration (g/dL), as measured after birth and documented in the medical record.

At the time of delivery until 5 days postpartum

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年11月21日

初级完成 (实际的)

2025年9月12日

研究完成 (实际的)

2026年10月30日

研究注册日期

首次提交

2024年4月8日

首先提交符合 QC 标准的

2024年4月10日

首次发布 (实际的)

2024年4月16日

研究记录更新

最后更新发布 (实际的)

2026年11月9日

上次提交的符合 QC 标准的更新

2026年11月4日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅